First‐Line Dapagliflozin, Metformin, or Combination Therapy in Type 2 Diabetes: Vascular and Molecular Outcomes of a Randomised Controlled Trial
Authors' conclusion
In treatment-naïve newly diagnosed T2DM, dapagliflozin produced significantly greater CIMT reduction versus metformin, accompanied by distinct sphingolipid and proteomic signatures suggesting pleiotropic cardioprotective mechanisms.
Study context
- Population
- Treatment-naïve adults with newly diagnosed T2Drandomised 1:1:1
- Participants
- 60 adults
- Comparison
- Dapagliflozin vs metformin vs dapagliflozin-metformin combination
- Metforminn = 19reference
- Dapagliflozinn = 20
- Combinationn = 21
- Primary endpoint
- Change in reactive hyperaemia index (RHI) from baseline
- Follow-up
- 12 weeks
Primary result
As reported in the abstract
Change in RHI
- Reactive hyperaemia index (RHI) did not differ significantly between groups
Secondary outcomes
| Outcome | Estimate | P value |
|---|---|---|
| CIMT reductionDapagliflozin vs Metformin · ANCOVA | −0.058 mm (95% CI −0.106 to −0.010) | P = 0.018 |
Pulse wave velocity (PWV)
- PWV changes were non-significant between groups
Exploratory sphingolipid profiling
- Dapagliflozin-specific downregulation of pro-inflammatory lactosylceramide species, particularly LacCer(d18:0) (AUC)
- 0.814
Exploratory proteomics, dapagliflozin vs metformin
- Upregulation of EpCAM and downregulation of endothelial adhesion molecules (JAM-A, PECAM-1, vWF) and tissue plasminogen activator with dapagliflozin vs metformin
Original publication
First‐Line Dapagliflozin, Metformin, or Combination Therapy in Type 2 Diabetes: Vascular and Molecular Outcomes of a Randomised Controlled Trial. Diabetes Obes Metab. Published 3 July 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →